sellWeak
Erica Jordan sold $9,096 of RVNC
Chief Commercial Officer at Revance Therapeutics, Inc.. 2,392 shares at an average of $3.80, traded Apr 16, 2024, filed Apr 17, 2024.
Warning score
15Value
$9,096
2,392 shares
Holdings after
114,864
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$9k at market
- 0Share of holdings soldSold 2.0% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001479290-24-000074, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 16, 2024 | SOpen-market sale Common Stock | -2,392 | $3.80 | $9,096 | 114,864 | Apr 17, 2024 |
Related signals
Other insiders at Revance Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | RVNCsell Revance Therapeutics, Inc. | David Hollander CMO & Global Therapeutics Lead | $16k 3,908 shares | -4% | |
| 36Weak | Revance Therapeutics, Inc. | Dwight Moxie CLO & GC | $41k 8,125 shares | -6% | |
| 43Moderate | Revance Therapeutics, Inc. | Tobin Schilke CFO | $47k 9,361 shares | -5% | |
| 41Moderate | Revance Therapeutics, Inc. | Dustin S Sjuts President | $46k 9,211 shares | -5% | |
| 37Weak | RVNCbuy Revance Therapeutics, Inc. | Mark J Foley CEO | $209k 30,000 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.